How to Maintain Pregnancy After Returning from IVF in Kyrgyzstan? Complete Guide to Medication Monitoring and Follow-up

Opening: Real Consultation Scenario

Module R: Practitioner Observation

Practitioner Observation: The Decisive Factor for Pregnancy Maintenance Outcome Lies Before Returning Home

As a overseas coordinator with 10 years of experience, I have handled hundreds of cases of patients returning from IVF in Kyrgyzstan. Patients with good pregnancy maintenance outcomes usually did three things before returning home: obtained complete medical records (including ovarian stimulation protocol, transfer records, embryo grading, medication plan), confirmed that medications could be legally carried into the country, and arranged in advance for a receiving hospital in China. Cases with problems were mostly due to information gaps — domestic doctors were unaware of the treatment plan in Kyrgyzstan, and the patients themselves could not clearly explain the medication details, making it impossible to formulate a precise pregnancy maintenance plan. Some patients, due to difficulty getting appointments or inconvenience in seeing a doctor after returning home, reduced or stopped medication on their own, eventually leading to decreased progesterone, contractions, or even miscarriage.

In summary, patients with smooth pregnancy maintenance often share three characteristics: ① Complete medical documents before returning home, ② Establishing a medical record within 48 hours after returning, ③ Maintaining regular follow-up with a domestic doctor. Conversely, common causes of pregnancy maintenance failure include incomplete medical records, medication interruption, and insufficient monitoring frequency.

Module A: Direct Answer to the Question

Core Answer: Never Stop Medication · Monitor Frequently · Establish Medical Record Early

Maintaining pregnancy after returning from IVF in Kyrgyzstan can be summarized by three key points: Never stop medication — luteal phase support drugs must not be interrupted; stopping for more than 24 hours may trigger contractions, leading to miscarriage; Monitor frequently — regularly test hCG, progesterone, and estradiol, usually 1–2 times per week, and adjust the plan dynamically based on results; Establish medical record early — visit the reproductive center or gynecology outpatient clinic of a local tertiary hospital within 72 hours after returning to establish a follow-up relationship, allowing the domestic doctor to fully understand your condition.

Specific implementation needs to be individualized based on the type of transfer cycle (artificial cycle / natural cycle / down-regulated cycle), embryo type (fresh embryo / frozen embryo / blastocyst), patient age, and previous pregnancy history. No single plan fits everyone.

Module I: Actual Process

Five-Step Process for Pregnancy Maintenance After Returning Home

Step 1: Document Preparation Before Returning Home (Kyrgyzstan Side)

• Detailed medical records: Ovarian stimulation protocol, transfer date, embryo grading, transfer cycle type, medication records.
• Medication prescription and drug information: Including generic name, brand name, dosage, usage, remaining course.
• Contact information of the attending physician (email or phone) in case the domestic doctor needs to communicate.
• Embryo culture and freezing records (if frozen embryo transfer), to understand embryo grade and freezing method.
• Passport, visa page, medical visa (if applicable), required for establishing medical records in some domestic hospitals.

Step 2: Rapid Medical Record Establishment After Returning Home (Within 72 Hours)

Take the above documents to the reproductive center or gynecology outpatient clinic of a local tertiary hospital. It is recommended to choose a hospital with a Recurrent Miscarriage Clinic or Reproductive Immunology Subspecialty. During the first visit, proactively inform the doctor that the embryo transfer was performed in Kyrgyzstan and provide all medical records. Based on this information, the doctor will create a follow-up file and order necessary tests.

Step 3: Doctor Evaluation and Plan Formulation

The domestic doctor will formulate an individualized pregnancy maintenance plan based on the medical records and current test results. Common luteal phase support medications include:

Medication	Route of Administration	Common Dosage	Notes
Dydrogesterone (Duphaston)	Oral	10mg tid or bid	Not affected by food; take missed dose promptly
Progesterone Injection	Intramuscular injection	20–40mg qd	Requires deep intramuscular injection; watch for local induration
Crinone (Progesterone Vaginal Gel)	Vaginal	90mg qd	Use in the morning; ensure cleanliness
Utrogestan (Progesterone Capsules)	Oral or Vaginal	100–200mg bid	Vaginal administration can reduce dizziness

The specific choice of plan should be based on the patient's progesterone level, liver function, tolerance, and economic cost.

Step 4: Regular Monitoring and Dynamic Adjustment

Key tests and their frequency during pregnancy maintenance:

• hCG: First test 10–14 days post-transfer, repeat after 48–72 hours to check doubling, then once weekly until around 8 weeks of pregnancy.
• Progesterone: Test simultaneously with hCG each time; target level >15 ng/mL; <10 ng/mL requires medication adjustment.
• Estradiol: Focus on patients with artificial cycle transfers; maintain within a certain range to support endometrial receptivity.
• D-dimer: Screen for pre-thrombotic state; elevation requires anticoagulation therapy.
• Thyroid function: Keep TSH <2.5 mIU/L; both hypothyroidism and hyperthyroidism affect pregnancy outcomes.

Step 5: Handling Special Situations

Seek immediate medical attention if the following occur: worsening abdominal pain, increased vaginal bleeding, abnormal discharge, fever. Early pregnancy ultrasound is scheduled at 6–7 weeks to confirm fetal heartbeat and yolk sac, and to rule out ectopic pregnancy and empty gestational sac.

Module C: Doctor's Perspective

Reproductive Doctor's Perspective: Information Symmetry is the Prerequisite for Pregnancy Maintenance

Many reproductive doctors emphasize in clinical discussions that the difficulty of cross-border IVF pregnancy maintenance lies not in the technology itself, but in information transfer. If domestic doctors cannot see the complete ovarian stimulation protocol, transfer records, and embryo grading, they cannot accurately assess the patient's endometrial receptivity and embryo potential, making it difficult to formulate a precise pregnancy maintenance plan. For example, luteal phase support plans differ completely between artificial cycle and natural cycle transfers; implantation timing also varies between blastocysts and D3 embryos, all of which affect the pregnancy maintenance strategy.

Doctors recommend that the more complete the medical records a patient brings back, the better the doctor can make correct decisions. Ideally, records should include: Ovarian stimulation medications and dosages, endometrial preparation protocol, transfer date, embryo grading (e.g., 4AA, 4BB), post-transfer medication plan, previous pregnancy history, and genetic counseling results (e.g., PGT report). Additionally, follow up with one hospital consistently to avoid information loss from frequently changing doctors.

Module G: Most Easily Overlooked Details

Five Most Easily Overlooked Details

• Time difference for medication: There is a 2–3 hour time difference between Kyrgyzstan and China. Adjust medication times to Beijing time and take medication at a fixed time daily to avoid fluctuations in blood concentration.
• Differences in drug names: The same active ingredient may have different brand names in different countries. For example, progesterone might be called Progesterone in Kyrgyzstan, while in China it is Progesterone Injection or Crinone. Verify the generic name and dosage to avoid purchasing the wrong product.
• Drug storage conditions: Progesterone injection should be protected from light; Crinone should be stored below 25°C; some medications require cold chain transport. Take appropriate insulation or cooling measures during the return trip.
• Emotions and endocrine system: Patients undergoing cross-border IVF bear dual pressure of time and cost. Anxiety can affect the endocrine system via the hypothalamic-pituitary-ovarian axis, thereby interfering with luteal function. Seek psychological support if necessary, or discuss safe mood regulation methods with your doctor.
• Uterine cavity environment assessment: If there is a history of repeated implantation failure or previous miscarriage, it is recommended to simultaneously evaluate the uterine cavity environment during pregnancy maintenance — hysteroscopy, endometrial biopsy, ERA, and immunohistochemistry (e.g., NK cells, T cells, cytokine profile) to rule out chronic endometritis or immune factors.

Module L: Interpretation of Key Indicators

Interpretation of Key Pregnancy Maintenance Indicators

Indicator	Reference Range	Abnormal Indication	Action
hCG (Human Chorionic Gonadotropin)	10–14 days post-transfer >50 IU/L; doubles every 48h	Slow doubling <66% or decline	Investigate ectopic pregnancy, abnormal embryo development; dynamic monitoring
Progesterone (P)	During luteal support >15 ng/mL	<10 ng/mL indicates luteal phase deficiency	Increase progesterone dose or change route of administration
Estradiol (E2)	Artificial cycle maintenance around 200–600 pg/mL	Significant drop may indicate luteal phase deficiency	Consider estradiol supplementation, adjust plan
D-dimer	Normal <0.5 mg/L (per lab standard)	Elevated indicates pre-thrombotic state	Low molecular weight heparin anticoagulation therapy, monitor coagulation function
TSH (Thyroid Stimulating Hormone)	Pregnancy <2.5 mIU/L	Elevated indicates hypothyroidism, decreased indicates hyperthyroidism	Correct with levothyroxine, recheck every 2–4 weeks

Note: The above reference ranges may vary slightly depending on the laboratory and individual differences. Refer to the report from your hospital for specifics.

Module M: Case Scenario Analysis

Analysis of Three Typical Scenarios

Module H: Most Common Pitfalls

Five Most Common Pitfalls

• Stopping or reducing medication on your own: Due to difficulty getting appointments, feeling good, or listening to non-professional advice, arbitrarily reducing the dose of luteal support drugs or stopping them — this is the most common cause of pregnancy maintenance failure. Luteal support must continue until the placental function is established (around week 10–12 of pregnancy) and should not be terminated early.
• Arbitrarily switching medications: Different progesterone formulations have different bioavailability and metabolic pathways. For example, switching from Crinone to Utrogestan, or from injection to oral form, requires evaluation by a doctor based on blood concentration and liver function; do not replace them on your own.
• Insufficient monitoring frequency: hCG and progesterone require dynamic monitoring. A single normal result does not mean it will remain normal. Some patients relax after one normal hCG test, only to find two weeks later that progesterone has dropped to 8 ng/mL, missing the window for intervention.
• Ignoring immune and coagulation factors: For patients with repeated implantation failure or a history of miscarriage, it is necessary to simultaneously screen for anticardiolipin antibodies, β2-glycoprotein, lupus anticoagulant, NK cell activity, homocysteine, and other immune and coagulation indicators during pregnancy maintenance. Simply increasing the progesterone dose cannot resolve immune-mediated miscarriage.
• Excessive pregnancy maintenance: Blindly using immunosuppressants (e.g., cyclosporine, intralipid, IVIG) or anticoagulants (e.g., low molecular weight heparin, aspirin) without clear indications increases the risk of bleeding and infection. All medications must be supported by laboratory indicators and clinical evidence.

Ending: Risk Reminder

---

This article is compiled based on clinical experience in assisted reproduction and cross-border medical coordination practices and is not a substitute for individual diagnosis and treatment. Please consult a licensed physician for specific plans.